First choIce Antidepressants: General Practitioner's Treatment Approach in the Czech Republic (FIAT)

First choIce Antidepressants: General Practitioner's Treatment Approach in the Czech Republic (FIAT)

According to the local guidelines (Recommendation for General Practitioners), the first choice Anti-Depressant (AD) in Major Depressive Disorder (MDD) in primary care should be selective serotonin reuptake inhibitors (SSRI), e.g. citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, in depression with anxiety and insomnia is preferable trazodone and in severer disorders mirtazapine. Despite all these molecules have a very good antidepressant effect, there are differences in side effect scale and tolerability.

The aim of this Study is describing of real treatment practice and MDD management in primary care - aimed to evaluate effectiveness of the treatments in depression and related symptoms: insomnia, anxiety, anhedonia and sexual dysfunction.

The primary objective of the Study is to describe the diagnostic process and treatment patterns in MDD- treatment of choice (pharmacologic with details of first choice antidepressant) in the office of GP's.

The secondary objective is to evaluate efficiency of the treatments in depression and related symptoms: insomnia, anxiety, anhedonia and sexual dysfunction and to monitor the type of side effects and comedication during the 8-weeks treatment.

Study Overview

• Status: Terminated
• Conditions: Adult Patients; Major Depressive Disorder Co-Occurrent With Anxiety; Newly Diagnosed Depression

Detailed Description

Research question:

What are the common clinical practices adopted by general practitioner - diagnostic process and treatment of choice (pharmacologic with details of first choice antidepressant) in patients with newly diagnosed depression and how the diagnosis is performed.

Data sources:

Validated questionnaires (PHQ-9, GAD-7, SHAPS), quality of sleep measures with wrist actigraphy monitor. Questions dedicated to sexual dysfunctions. Data about patient's history, diagnosis, treatment and relevant side effects collected directly to the database.

Variables:

Primary Variables Sex and age of the patient. Type of treatment - one of the first line antidepressants available in GP's office (SSRIs, trazodone or mirtazapine) and specifications regarding the treatment approach: initiation dose of treatment, therapeutic dose of treatment, date of the dose increase, total day dose of treatment.

Secondary Variables Insomnia, anxiety and anhedonia will be evaluated by differences of scores of questionnaires (before and after treatment). Sexual dysfunction will be evaluated by differences of answers (before and after treatment).

• Proportional change in total sleep time (TST) before (1 day) /after (8 weeks) the initiation of treatment (TST is defined as the amount of actually sleep time in a sleep episode; this time is equal to the total sleep episode less the awake time).
• Sleep efficiency (time asleep / (total time in bed - time to fall asleep).
• Sleep latency (the duration of time from bedtime, to the onset of sleep).
• Sleep bouts (the number of occurrences of a bout (or multiple bouts), the average length of the bout(s), the total time spent in the bouts, and the total count level of the bouts).
• Sleep fragmentation index (index of restlessness during the sleep period expressed as a percentage).

Monitoring of the type of side effects and comedication during the 8-weeks.

Statistical methods:

Categorical parameters will be described by absolute and relative frequencies. Relative frequencies will be calculated based on the number of patients in relevant subgroup. Continuous parameters will be described by mean and standard deviation (SD) and median with minimum and maximum, together with the total number of non-missing observations.

The differences of the scores of the questionnaires (measured before and after treatment) will be also described by standard characteristics as mean (SD) and median (minimum-maximum). These differences will be tested by paired test (paired t-test or paired Wilcoxon test in dependence on meeting prerequisites). Differences with p-values < 0.05 will be statistically significant (analysis will be performed with level of significance α=0.05).

All statistical tests and confidence intervals will be of exploratory nature.

• Study Type: Observational
• Enrollment (Actual): 28

Contacts and Locations

• Study Contact: Name: Adriana Vavříková, MSc.; Phone Number: +420 731 520 941; Email: adriana.vavrikova@angelinipharma.com
• Study Contact Backup: Name: Martina Nováčková, MSc.; Email: novackova@biostatistika.cz

Study Locations

• Czechia
  • Brno, Czechia, 602 00
    • MUDr. František Rolinek, s.r.o.
  • Brno, Czechia
    • Artemisia všeobecné lékařství, s.r.o.
  • Hradec Králové, Czechia, 50009
    • MEDIGATE Care s.r.o.
  • Litoměřice, Czechia, 14000
    • AAAmbulance, s.r.o.
  • Praha, Czechia, 190 00
    • Poliklinika Prosek
  • Praha, Czechia, 70200
    • PragMed, s.r.o.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adult patients with newly diagnosed depression included in the Non-Interventional Study (NIS) must be assigned to the therapy before and independently with respect to the decision of being enrolled in the Study.

Description

Inclusion Criteria:

• Signing of the Inform Consent Form (Personal Data Protection Consent included)
• Adults male and female newly diagnosed with depression in care of the general practitioner

Exclusion Criteria:

• Patients previously treated with depression or patients treated by a psychiatrist
• Pregnancy and breast-feeding
• Acute myocardial infarction
• Significant risk of suicide
• Concomitant antidepressant medication

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Description of the type of antidepressant	The variable type of antidepressant will be observed and evaluated.	patient duration: from enrollment to end of treatment for 8 weeks
Description of the dose of the antidepressant	The difference between the therapeutic and prescribed dose of antidepressant will be computed as therapeutic dose - prescribed dose.	patient duration: from enrollment to end of treatment for 8 weeks
Description of the increase of dose	The variable the increase of dose will be computed as changes of dose of comedication drug at the end of follow-up - dose of the drug at the start of follow-up.	patient duration: from enrollment to end of treatment for 8 weeks
Description of the time on an antidepressant without change of dose	Time on an antidepressant without change of dose will be computed as date of increase of dose - date of enrolment visit.	patient duration: from enrollment to end of treatment for 8 weeks
Description of the maximum daily dose of antidepressant	The variable maximum total daily dose will be observed and evaluated.	patient duration: from enrollment to end of treatment for 8 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Treatment efficiency - insomnia - change in total sleep time	Data about insomnia will be collected via a wireless-enabled wrist-worn actigraphy device. Variable proportional change in total sleep time is defined as the amount of actual sleep time in a sleep episode; this time is equal to the total sleep episode less the awake time.	patient duration: from enrollment to end of treatment for 8 weeks
Treatment efficiency - insomnia - sleep efficiency	Data about insomnia will be collected via a wireless-enabled wrist-worn actigraphy device. Variable sleep efficiency is defined as time asleep / (total time in bed - time to fall asleep).	patient duration: from enrollment to end of treatment for 8 weeks
Treatment efficiency - insomnia - sleep latency	Data about insomnia will be collected via a wireless-enabled wrist-worn actigraphy device. Variable sleep latency is defined as the duration of time from bedtime, to the onset of sleep.	patient duration: from enrollment to end of treatment for 8 weeks
Treatment efficiency - insomnia - sleep bouts	Data about insomnia will be collected via a wireless-enabled wrist-worn actigraphy device. Variable sleep bouts is defined as the number of occurrences of a bout (or multiple bouts), the average length of the bout(s) will be evaluated and described.	patient duration: from enrollment to end of treatment for 8 weeks
Treatment efficiency - insomnia - sleep bouts	Data about insomnia will be collected via a wireless-enabled wrist-worn actigraphy device. Variable sleep bouts is defined as the number of occurrences of a bout (or multiple bouts), the total time spent in the bouts will be evaluated and described.	patient duration: from enrollment to end of treatment for 8 weeks
Treatment efficiency - insomnia - sleep bouts	Data about insomnia will be collected via a wireless-enabled wrist-worn actigraphy device. Variable sleep bouts is defined as the number of occurrences of a bout (or multiple bouts), the total count level of the bouts will be evaluated and described.	patient duration: from enrollment to end of treatment for 8 weeks
Treatment efficiency - insomnia - sleep fragmentation index	Data about insomnia will be collected via a wireless-enabled wrist-worn actigraphy device. Variable sleep fragmentation index is defined as the index of restlessness during the sleep period expressed as a percentage.	patient duration: from enrollment to end of treatment for 8 weeks
Treatment efficiency - anxiety	Data about anxiety will be collected via the validated self-administered questionnaire - Generalized Anxiety Disorder Questionnaire (GAD-7). Differences in the score of the questionnaire (measured before and after treatment) will be computed as the score of the questionnaire after treatment - the score of the questionnaire before treatment. Scale values: GAD-7 - total scores ranged from 0 to 21. A higher total GAD-7 score indicated higher levels of the present state of anxiety.	patient duration: from enrollment to end of treatment for 8 weeks
Treatment efficiency - anhedonia	Data about anhedonia will be collected via the validated self-administered questionnaire - Snaith-Hamilton Pleasure Scale (SHAPS). Differences in the score of the questionnaires (measured before and after treatment) will be computed as the score of the questionnaire after treatment - the score of the questionnaire before treatment. Scale values: SHAPS - total scores ranged from 0 to 14. A higher total SHAPS score indicated higher levels of the present state of anhedonia.	patient duration: from enrollment to end of treatment for 8 weeks
Treatment efficiency - level of depression	Data will be collected via the validated self-administered questionnaire-Patient Health Questionnaire-9 (PHQ-9) - Patient Health Questionnaire. Differences in the score of the questionnaire (measured before and after treatment) will be computed as the score of the questionnaire after treatment - the score of the questionnaire before treatment. Scale values: PHQ-9 - total scores ranged from 0 to 27. A higher total PHQ-9 score indicated higher levels of the present state of depression.	patient duration: from enrollment to end of treatment for 8 weeks
Treatment efficiency - sexual dysfunction	Sexual dysfunction data will be collected via dedicated questions. Answers to questions about sexual dysfunction at the start and end of treatment will be compared and evaluated.	patient duration: from enrollment to end of treatment for 8 weeks
Treatment efficiency - adverse events	Monitoring of the type of side effects during the 8-weeks. The summary of Adverse events (AE) / Severe Adverse Events (SAE) will present the number and percentage of patients who had at least one AE. The data on AEs/SAEs will be listed.	patient duration: from enrollment to end of treatment for 8 weeks
Monitoring of the type of comedication during the 8-weeks	Monitoring of the comedication during the 8-weeks. Changes in comedications between the initial and terminal visits will be evaluated and described.	patient duration: from enrollment to end of treatment for 8 weeks

Collaborators and Investigators

• Sponsor: Angelini Pharma Česká republika s.r.o.
• Collaborators: National Institute of Mental Health (NIMH); Institut biostatistiky a analýz, s.r.o. (IBA); MINDPAX, s.r.o.
• Investigators: Principal Investigator: Filip Španiel, MD, PhD, National Institute of Mental Health (NIMH)

Study record dates

Study Major Dates

• Study Start (Actual): October 15, 2021
• Primary Completion (Actual): June 10, 2023
• Study Completion (Actual): June 30, 2023

Study Registration Dates

• First Submitted: January 12, 2022
• First Submitted That Met QC Criteria: March 18, 2022
• First Posted (Actual): March 23, 2022

Study Record Updates

• Last Update Posted (Actual): July 18, 2023
• Last Update Submitted That Met QC Criteria: July 17, 2023
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Keywords: depression; insomnia; MDD; anxiety; real world data; anhedonia; first choice antidepressant; MindG bracelets; sexual disfunction
• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Mood Disorders; Depression; Depressive Disorder; Depressive Disorder, Major
• Other Study ID Numbers: 153(B)LM21212

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No